Schizophrenia: Epidemiology and Etiology

Schizophrenia: Epidemiology and Etiology - Epi Basics: Numbers & Notables

• Lifetime prevalence: ~1% worldwide. Annual incidence: 10-40/100,000.
• Age of Onset (Peak):
  • Males: 18-25 yrs (earlier, poorer prognosis).
  • Females: 25-35 yrs (bimodal peaks, 2nd perimenopausal).
• Sex Ratio: M:F ~1.4:1. Males: more negative symptoms, earlier onset.
• Risk Factors: Urbanicity, migration, lower SES (downward drift).
• Comorbidity: High with substance use (cannabis ↑ risk).
• Mortality: ↑ (SMR 2-3); suicide risk significant (~5-10%).

⭐ Lifetime prevalence of schizophrenia is consistently around 1% across diverse populations globally.

Schizophrenia: Epidemiology and Etiology - Gene Scene: Family Ties

• Strong genetic component; heritability estimated at ~80%.
• Risk significantly increases with degree of genetic relatedness:
  • General population: ~1%.
  • Second-degree relative (e.g., uncle, grandparent): ~3%.
  • First-degree relative (e.g., parent, sibling, child): ~10%.
  • Dizygotic (DZ) twin / Child with one affected parent: 10-15%.
  • Child with two affected parents: ~40%.
  • Monozygotic (MZ) twin: 40-50%.
• Polygenic inheritance: multiple genes with small, cumulative effects contribute; not Mendelian.
• Adoption studies confirm strong genetic influence, separating genetics from environment.

⭐ Concordance in MZ twins (40-50%) versus DZ twins (10-15%) starkly highlights the substantial genetic loading in schizophrenia development.

Schizophrenia: Epidemiology and Etiology - Brain Buzz: Chemical Chaos

• Central Theme: Neurotransmitter dysregulation, primarily involving dopamine, glutamate, and serotonin, underpins psychotic symptoms.
• Dopamine (DA) Hypothesis:
  • Mesolimbic pathway: Hyperactivity (↑DA) linked to positive symptoms (e.g., hallucinations, delusions).
  • Mesocortical pathway: Hypoactivity (↓DA) linked to negative symptoms (e.g., apathy, anhedonia) and cognitive impairment.
  • Nigrostriatal pathway: Antipsychotic DA antagonism can cause Extrapyramidal Symptoms (EPS).
  • Tuberoinfundibular pathway: DA antagonism can lead to hyperprolactinemia.
• Glutamate Hypothesis:
  • Hypofunction of NMDA receptors is crucial. Drugs like PCP/ketamine (NMDA antagonists) induce psychosis-like states.
  • Impaired glutamatergic signaling affects DA pathways and contributes to negative/cognitive symptoms.
• **Serotonin (5-HT):
  • Modulates dopamine activity. 5-HT2A receptor antagonism is a key mechanism of atypical antipsychotics, improving negative symptoms and reducing EPS risk.
• Other Contributors:
  • GABAergic system: Reduced inhibitory input, especially in prefrontal cortex.
  • Neuroinflammation: Microglial activation, cytokine dysregulation.

⭐ Dysfunction in the brain's glutamate system, particularly NMDA receptor hypofunction, is increasingly recognized as a core component of schizophrenia's pathophysiology, potentially driving dopamine dysregulation.

Schizophrenia: Epidemiology and Etiology - Enviro-Events: Triggers & Trauma

• Stress-Diathesis Model: Gene-environment interaction.
• Prenatal & Perinatal Factors:
  • Maternal infections (e.g., influenza, rubella, toxoplasmosis), malnutrition, stress.
  • Obstetric complications (e.g., hypoxia, preeclampsia, low birth weight, prematurity).
  • Advanced paternal age (>50 yrs).
  • Season of birth (late winter/early spring).
• Childhood & Adolescent Factors:
  • Childhood trauma (abuse, neglect, bullying).
  • Urban upbringing (dose-response effect).
  • Migration (esp. 1st/2nd gen. minorities).
  • Cannabis use (adolescence, high-THC): ↑ risk 2-5 fold.
• Psychosocial Triggers:
  • High Expressed Emotion (EE) in family (criticism, hostility, emotional over-involvement) → ↑ relapse.
  • Acute stressful life events.

⭐ Adolescent cannabis use, especially high-potency (THC-rich) strains, is a significant modifiable risk factor, increasing schizophrenia risk by 2-5 times.

High‑Yield Points - ⚡ Biggest Takeaways

• Global prevalence ~1%; males affected slightly more and often earlier.
• Peak onset: Males 18-25 yrs, females 25-35 yrs & perimenopausal peak.
• Strong genetic link: Heritability ~80%; 1st-degree relatives ~10% risk, MZ twins ~40-50%.
• Dopamine hyperactivity (mesolimbic) is key; glutamate hypofunction (NMDA) also implicated.
• Environmental risks: Perinatal insults, urbanicity, migration, adolescent cannabis use.
• Neurodevelopmental disorder with gene-environment interactions considered crucial.